◇Clinical Pharmacology / Pharmacometrics Review Agent

PopPK/ER Evidence Review Agent

Upload PDF, Word, Excel, CSV, or paste PopPK/ER text. The FastAPI backend extracts material, retrieves review knowledge, calls your server-side LLM API, and exports Word/PDF reports.

FastAPI backendFile parsingRAG knowledge baseWord/PDF export

Security model

The browser never receives your LLM API key. The frontend calls the FastAPI backend, and the backend reads API keys from server-side environment variables.

↑

Input materials

Paste text and/or upload files for review.

Approx. 55 pasted words

▤

Review output

Source: Demo fallback

Decision-readiness rating

Major revision needed

The package may support further discussion, but it is not yet strong enough for a confident no-dose-adjustment conclusion. The main gap is the translation of statistically significant covariate effects into clinically interpretable exposure and outcome evidence.

1

Critical

1

Major

0

Minor

2

Reg questions

!

Issue tracker

Severity, rationale, and recommended action.

Critical

Dose conclusion may be stronger than the evidence supports

The text states that no dose adjustment is needed across all body-weight groups, but it does not show exposure distributions by body-weight category or whether high-weight patients remain within the clinically relevant exposure range.

Recommended action: Add body-weight stratified simulations and compare predicted exposure with the observed exposure range supporting efficacy and safety.
Major

Covariate effect is not translated into clinical relevance

Body weight is identified as a statistically significant covariate on clearance, but the magnitude of exposure reduction and its clinical meaning are not described.

Recommended action: Report median and 5th/95th percentile exposure by body-weight group and discuss whether differences are clinically meaningful.
✓

Completeness checklist

PopPK/ER package readiness.

Data source and analysis setMissing detail
Structural model summaryPartial
Covariate modelPartial
Model diagnostics / VPCNot shown
?

Potential regulatory questions

Likely FDA/EMA/NMPA-style questions.

  1. 1How do you justify no dose adjustment in high body-weight patients given the effect of body weight on clearance?
  2. 2Which exposure metric was used for exposure-response analysis, and why was it selected?
≡

Recommended additional analyses

Analyses that could strengthen the evidence package.

  • Provide body-weight stratified exposure simulations with median and 5th/95th percentiles.
  • Overlay simulated exposure distributions with observed exposure ranges supporting efficacy and safety.
§

Suggested regulatory-style language

Draft language users can adapt after expert review.

Although body weight was identified as a covariate on clearance, the clinical relevance of this effect should be interpreted using model-based exposure simulations across body-weight categories.
⚗

Beginner explanation

Designed for users who are not PopPK experts.

A statistically significant covariate does not automatically require dose adjustment. The key question is whether the exposure change is clinically meaningful.